sur BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Solutions Updates on Sublingual Drug Delivery Progress
Vancouver-based BioNxt Solutions Inc. has provided a detailed update regarding its advancements in sublingual drug delivery technologies. The company's primary focus is on developing a sublingual Cladribine film aimed at treating multiple sclerosis. Current progress includes regulatory documentation and the preparation for a human bioavailability study.
In addition to Cladribine, BioNxt is advancing programs for Everolimus and Semaglutide. Everolimus, commonly used in organ transplants and cancer treatment, is being developed in a sublingual format. Meanwhile, the Semaglutide project targets the growing metabolic disease sector.
The company's intellectual property foundation strengthens with patent protection in Europe and Eurasia for its Cladribine technology. Further applications are progressing in the US. These developments support BioNxt’s commitment to leveraging its thin-film platform across various therapeutic areas.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioNxt Solutions Inc.